Biotinidase deficiency is an autosomal recessively inherited disorder characterized by neurological and cutaneous abnormalities. We have developed a transgenic knock-out mouse with biotinidase deficiency to better understand aspects of pathophysiology and natural history of the disorder in humans. Neurological deficits observed in symptomatic mice with biotinidase deficiency are similar to those seen in symptomatic children with the disorder. Using a battery of functional neurological assessment tests, the symptomatic mice performed poorly compared to wild-type mice. Demyelination, axonal degeneration, ventriculomegaly, and corpus callosum compression were found in the brains of untreated, symptomatic enzyme-deficient mice. With biotin treatment, the symptomatic mice improved neurologically and the white matter abnormalities resolved. These functional and anatomical findings and their reversal with biotin therapy are similar to those observed in untreated, symptomatic and treated individuals with biotinidase deficiency. The mouse with biotinidase deficiency appears to be an appropriate animal model in which to study the neurological abnormalities and the effects of treatment of the disorder.
Introduction
Biotin is the coenzyme for all four human biotin dependent carboxylases: propionyl-CoA carboxylase (PCC), β-methylcrotonyl-CoA carboxylase (MCC), pyruvate carboxylase (PC), and acetyl-CoA carboxylase (ACC) (Moss and Lane, 1971) . PCC is involved in the catabolism of several branched-chain amino-acids and odd-carbon chain fatty acids by converting propionyl-CoA to methylmalonyl-CoA, which then enters the tricarboxylic acid cycle. MCC is involved in leucine catabolism by the conversion of β-methylcrotonyl-CoA to β-methylglutaconyl-CoA. PC catalyzes the conversion of pyruvate to oxaloacetate, an intermediate in the biosynthesis of phosphoenolpyruvate and, ultimately, to glucose. ACC catalyzes the formation of malonyl-CoA from acetyl-CoA, the first committed step in the biosynthesis of fatty acid. Deficiencies of the carboxylases and the consequential accumulation of abnormal metabolic intermediates have profound effect on other pathways resulting in severe clinical consequences (Wolf and Feldman, 1982) . Holocarboxylase synthetase (HCS) catalyzes the covalent attachment of biotin to ε-amino groups of the conserved lysyl-residues of apocarboxylases; thereby transforming apocarboxylases to holocarboxylases (Sweetman, 1981) . Biocytin (biotinyl-ε-lysine) and small biotinyl-peptides are released during the proteolytic turnover of the holocarboxylases. Biotinidase hydrolyzes biocytin and small biotinyl-peptides, thus recycling free biotin (Craft et al., 1985; Pispa, 1965) . Thus, children with genetic defect in either HCS or biotinidase results in multiple carboxylase deficiency (MCD).
Biotin deficiency in humans is rare because biotin is continuously being recycled by the action of biotinidase. Biotin is also obtained exogenously from the diet, either directly as free biotin from sources, such as fruits and vegetables, or in a protein-conjugated form which must be made bioavailable by biotinidase. The quantity of free biotin that comes directly from the diet is small. Thus, biotinidase plays a crucial role in maintaining the free biotin pool in the body and deficient biotinidase activity results in late-onset MCD in children. The known and putative functions of biotinidase are shown in the biotin cycle in Fig. 1 .
Biotinidase deficiency, if untreated, can cause serious neurological and cutaneous consequences (Wolf, 2001; Wolf et al., 1983a) . Children with profound biotinidase deficiency (less than 10% of mean normal serum activity) can exhibit neurological symptoms, including hypotonia, seizures, ataxia, optic atrophy, sensorineural hearing loss, spastic paraparesis and developmental delay (Wolf, 1992 
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